Kornimate/medical-research-clean huggingface dataset:
does allopurinol prolong a treated, acute gout flare?

Conditions: Gout

Summary: this is a double blind placebo controlled study to determine whether starting allopurinol during a treated acute gout attack will have any effect on the duration of the attack.

traditional teaching holds that starting allopurinol during an acute gout attack will prolong the attack. recent expert opinion from the american college of rheumatology guidelines is that allopurinol may be started during an acute, treated gout attack. this study is designed to test the hypothesis that allopurinol does not prolong an acute, treated gout attack. patients will either take allopurinol capsules or and identical capsule containing no allopurinol (placebo) over 28 days, starting within 72 hours of a gout attack that is being treated with other standard measures. during the study, neither the patient nor the examiner will know what pills are being taken. the time to resolution of the attack is the primary outcome measure. pain level, serum uric acid level, and complications of therapy will also be monitored. a minimum of 32 patients completing the study are needed for a meaningful conclusion.

Eligibility criteria:
inclusion criteria requires both of: * crystal proven gout, and * an acute gout attack within 72 hours of first treatment plus one of the following: * at least 2 gout attacks in past 12 months * tophus * nephrolithiasis * 24hr urine uric acid greater than 1000mg exclusion criteria: * inability to return for examinations * glomerular filtration rate (calculated) less than 50 milliliters per minute * allopurinol use in past 6 months * ongoing cancer therapy * concomitant azathioprine or cyclophosphamide * any one of the following liver enzymes greater than 1.25 times the upper limit of normal: * ast \[aspartate aminotransferase\] * alt \[alanine aminotransferase\] * alkaline phosphatase * pre-gout pain in involved joint of more than 3 on a scale of 1-10 * neurologic deficit around the involved joint

Keywords: gout allopurinol
pilates and the pelvic floor: a quasi-experimental study

Conditions: Pregnancy; Perineum; Injury; Pilates Method; Episiotomy Wound

Summary: in this paper, it is postulates that in pregnant women, the practice of pm led by a qualified professional for a period of four weeks can reduce the incidence of pelvic floor dysfunction (pfd) by decreasing the number of birth injuries.

it is postulated that in pregnang women, the practice of pm can reduce the severity of birth injuries. our main objective was to determine the effectiveness of a pm program to reduce the incidence and degree of intrapartum perineal injuries as a way to reduce the incidence of female pfd. secondary objectives were: assess the role of a mp program on the systolic and diastolic blood pressure. determine the effect of a mp program on body weight (bmi). it is a parallel group clinical trial with an allocation ratio of 1:2. all pregnant women will be informed about the nature of the clinical trial. there will be no differences in the pregnant´s follow-up because it will be performed by two same pilates monitor with the same formation. once the pregnant women is assigned to an arm of the study, those assigned to the intervention group will be sent to the pilates monitor to explain and initiate the exercise of mp program while the control group will be informed to maintain their usual monitoring of pregnancy. in the initial visit, the type of physical activity will be evaluated by filling in the international physical activity questionnaire (ipaq).

Eligibility criteria:
inclusion criteria: * to go to the maternal education program. * give your written consent to participate in the study. * singleton pregnancy. * low-risk pregnancy. * no contraindication to physical exercise. * age equals or more than 18 years old. excusion criteria: * pregnant women with poor pregnancy control. * difficulty in speaking or understanding spanish. * required a c-section during delivery. * refusal to participate in the study.

Keywords: nursing midwifery nurse pilates method pelvic floor injuries episiotomy pregnancy
impact of the characteristics of acute renal failure in intensive care on the long-term renal prognosis: prospective multicenter cohort study

Conditions: Acute Kidney Injury; Transient Acute Renal Failure; Persistent Acute Renal Failure

Summary: the purpose of this study is to assess the impact of acute kidney injury (aki) characteristics on long-term renal prognosis in intensive care unit (icu) patients.

this study will be a multicentre prospective observational study. the make evaluation after different kind of acute kidney injury (maki) study will be conducted in 4 intensive care units (icu) in clermont-ferrand, france. an information form about the study will be given to each icu patients hospitalized more than 24 hours. this form will be given to their support person if it is not possible. data during icu stay related to renal function of patients included in the study will be collected. if available data related to their baseline kidney function (before icu hospitalisation) will be collected. the patients will be classified into 3 groups based on the occurrence of aki and its duration: 1) patients without aki during their stay, 2) patients who had a transient aki episode (defined as recovery within 48 hours of onset), and 3) patients who had a persistent aki episode during their stay.

Eligibility criteria:
inclusion criteria: * patients who are hospitalized for more than 24 hours in icu will be eligible to participate in the study. exclusion criteria: * patients who are younger than 18 years, * those who are pregnant, * those who have chronic extrarenal epuration before their admission to the icu, * those who are admitted for kidney transplantation, * those under the safeguard of justice, and those who refuse to participate in the study.

Keywords: follow-up intensive care unit chronic kidney disease
single pill to avert cardiovascular events

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to determine whether a polipill improved the compliance with treatment compared to usual care that use two or more drugs,in patients at high cardiovascular risk or previous cardiovascular disease.


Eligibility criteria:
inclusion criteria: * adults age ≥ 18 years old; * patient that could written informed consent; * patient with current atherothrombotic cardiovascular disease or at high cardiovascular risk, defined as: * patients with previous coronary artery disease (miocardial infarction, estable or instable angina pectoris or coronary revascularization procedures); * patients with previous miocardial infarction, defined as medical registry (with documentation of at least 2 criterias: clinical symptoms,patological electrocardiogram and elevation of cardiac enzymes- ck-mb and/or troponin); * patients with previous brain ischemia (stroke or transient ischemic attack) * patients with confirmed previous peripheral arterial disease (coronary artery bypass procedures or angioplasty or amputation due peripheral arterial disease) * patients with no established cardiovascular disease but at high cardiovascular risk, defined as 15% or more in 5 years (using the anderson framingham scale, 1991) exclusion criteria: * contraindication for any of the polipill * if the physician opinion is that terapeutical change could harm the patient (for example, heart failure, need of high beta blocker dose for treatment angina symptons and for the atrial fibrillation rhythm,severe hypertension \[degree 3\], malignant hypertension or renal insufficiency * acute clinical conditions/ surgeries * psychiatry clinical conditions(for example, schizophrenia, serious depression) * pregnant or lactation women * women at fertile period mulheres not using effective contraceptive methods (oral contraceptive, condom, intrauterine device) * liver siseases (ast/alt/fa upon 3 x normal superior limits / bilirrubin upon 1,5 x normal superior limits / diagnosed liver cirrhosis * renal disfunction (any laboratorial exams upon 3 x normal superior limits) * previous participation on other clinical trial * the participant is unable or refuse to give informed consent.

Keywords: polypill, compliance, cardiovascular disease
remotely monitoring patients with chronic conditions in their home

Conditions: CHF

Summary: study will collect data from the home using the cova monitoring system. data will be captured and retrospectively analysis to determine if the data provided can alert clinician about a patient's declining health.

study will collect data from the home using the cova monitoring system. data will be captured and retrospectively analysis to determine if the data provided can alert clinician about a patient's declining health. data from the cova monitoring system will be compared against electronic health records to determine if the data captured will provide insight into a patient's overall health. additionally, user compliance will be monitored

Eligibility criteria:
inclusion criteria: * chronic disease including chf * currently receiving home health care * recent discharge for a chf event exclusion criteria: * skin reaction to electrodes * inability to take measurements due to low bmi
role of montelukast in the management of chronic rhinosinusitis with nasal polyps.

Conditions: Montelukast; Chronic Rhinosinusitis With Nasal Polyps

Summary: the aim of the work is to examine the efficacy of montelukast as an adjunct to steroid therapy in patients with chronic rhinosinusitis with nasal polyps.

population and methods the study will be conducted at the otorhinolaryngology department in assiut university hospital. * study design: prospective randomized controlled trial. * . * methodology: after fulfilling all inclusion and exclusion criteria all patients will be subjected to a. full history taking including : 1. personal history 2. history of sinonasal symptoms (nasal obstruction, nasal discharge, headache, hyposmia, sneezing, itching, facial pain...etc) 3. history of nasal surgery. 4. other ent symptoms 5. general symptoms suggestive of atopy 6. history of general medical illness. b. examination : * 1. general examination. * 2. full ent examination. * 3. nasal endoscopy. c. investigations : multi-slice computer tomography (msct) of nose and paranasal sinuses axial, coronal and sagittal cuts without contrast . d. management : patients will be divided into 2 equal groups. patients in group a will be treated with fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 monthes and oral prednisolone 40 mg/day for two weeks. subjects in treatment group b will receive topical and systemic steroids in an identical regimen only. .

Eligibility criteria:
inclusion criteria: * - 1- adult patients (aged 18 years and over) * 2- bilateral denovo nasal polyps confirmed by nasal endoscopy and ct scan. exclusion criteria: * - 1- crs patients without nasal polyposis. * 2- patient with unilateral nasal polyp. * 3- revision cases (history of previous surgical treatment). * 4- patient with fungal rhinosinusitis.. * 5- pregnancy and lactation. * 6- malignancies.

Keywords: montelukast chronic rhinosinusitis with nasal polyps
serum estradiol (e2) levels in breast cancer patients during endocrine therapy by high performance liquid chromatography-tandem mass spectrometry (lc-ms /ms)

Conditions: Breast Cancer

Summary: the investigators intend to conduct a prospective cohort study to detect e2 levels during endocrine therapy in chinese breast cancer patients using lc-ms/ms methods, and to determine the proportion of patients with premenopausal e2 levels (ofr or e2 insufficiency) during ais or ful endocrine therapy. to further explore the correlation between serum e2 levels and the efficacy of endocrine therapy in chinese patients, so as to ensure the safety and efficacy of endocrine therapy for patients, and pave the way for further providing more accurate individualized treatment programs.


Eligibility criteria:
inclusion criteria: * over 18 years old; * histologically confirmed breast cancer; * patients with early breast cancer (including natural menopause and artificial menopause using lhrha), or patients with advanced breast cancer (including natural menopause and artificial menopause using lhrha) who use ais (letrozole, anastrozole or exemestane) as adjuvant endocrine therapy, first-line cdk4/6 inhibitors (palbociclib, dalpiciclib, abemaciclib or ribociclib) +ai endocrine therapy, second-line cdk4/6 inhibitors (palbociclib, dalpiciclib, abemaciclib or ribociclib) + fluvestrant (ful) endocrine therapy; * patients with needs for hormone testing; * standard treatment, complete clinical data, including complete efficacy evaluation and follow-up data. exclusion criteria: * breast cancer patients using tam endocrine therapy; * in advanced patients, ais exceeded first-line use (that is, in advanced disease, one endocrine therapy regimen had been used and failed), and ful exceeded second-line use (that is, more than one endocrine therapy regimen had been used and failed)

Keywords: lc ms/ms estradiol
the prediction of preeclampsia/toxemia in twin pregnancy

Conditions: Preeclampsia/Toxemia

Summary: the purpose of this study is to finout whetere uterinae artery flow , pp13 and endogolin levels in the serum and kongo red in the urine can predict preeclamsia toxemia in twin pregnancies.


Eligibility criteria:
inclusion criteria: * a women with a vaiable twin pregnany exclusion criteria: * women with thrombophilya * women terated with anticoagolant * women with vascular disease

Keywords: preeclampsia toxemia twin pregnancy pp13 prediction kongo red
jasap: japanese aggrenox stroke prevention vs. aspirin programme

Conditions: Cerebrovascular Accident

Summary: phase iii study to compare the preventive effect of recurrent brain infarction and safety of aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily


Eligibility criteria:
inclusion criteria: patients with a diagnosis of cerebral infarction (excluding cardiogenic cerebral embolism) who meet the diagnostic criteria based on the national institute of neurological disorders and stroke (ninds) ad hoc committee's classification of cerebrovascular disease iii. 1. patients who have had an onset of cerebral infarction, the time of which is known, between 1 week and 6 months before the time of enrolment (including first and recurrent cerebral infarctions) 2. patients who are 50 years or older 3. patients whose neurological signs and symptoms are considered to be stable by the investigator or sub-investigator 4. patients with a finding corresponding to the responsible focus confirmed by head x-ray computerised tomography (ct) or magnetic resonance imaging (mri) 5. patients who have at least two of the following risk factors: * diabetes * hypertension (systolic blood pressure is 140 mmhg or higher or diastolic blood pressure is 90 mmhg or higher) or under treatment of hypertension * smoker (at the time of onset of cerebral infarction) * obesity (body mass index (bmi) is more than 25 kg/m2) * previous vascular disease (stroke, acute myocardial infarction or peripheral arterial disease before the onset of cerebral infarction) * end-organ damage (retinopathy, left ventricular hypertrophy (lvh) or microalbuminuria) * hyperlipidaemia exclusion criteria: 1. patients with a diagnosis of brain disorders with a bleeding risk such as brain haemorrhage, subarachnoid haemorrhage, cerebral arteriovenous (av) malformation, cerebral av aneurysms and brain tumours 2. patients with complications of cardiac disorders (atrial fibrillation, mitral valve stenosis, severe cardiac valve disorders) that may provide an embolic source for cerebral embolism 3. patients having had acute coronary syndromes (acute myocardial infarction, unstable angina) within 6 months after enrolment in this study 4. patient with hypersensitivity to dipyridamole preparations 5. patients with a history of drug allergy to acetylsalicylic acid (asa) or aspirin asthma 6. patients with a history of peptic ulcer 7. patients having undergone arterial reconstruction after development of cerebral infarction 8. patients with very severe impairment (4 or 5 on modified rankin scale) 9. patients with bleeding or bleeding tendencies (haemophilia, haemorrhage urinary tract, vitreous haemorrhage, etc.) 10. patients with severe hypertension (systolic blood pressure is 180 mmhg or higher or diastolic blood pressure is 110 mmhg or higher) 11. patients with complications such as serious cardiac, renal and hepatic disorders 12. patients with a malignant tumour or having had a tumour treatment in the past 5 years 13. women who are or may be pregnant or lactating women
balance, walking speed, quadriceps femoris muscle strength and quality of life in falling and non-falling individuals with copd

Conditions: Copd

Summary: a descriptive study evaluating balance, gait speed, quadriceps femoris muscle strength and quality of life in individuals with chronic obstructive pulmonary disease (copd) who fell and did not fall.

falls in the elderly can have devastating consequences. the ability to maintain stability and balance is critical for functional independence, mobility, and avoidance of falls in activities of daily living. an impaired balance is associated with an increased risk of falls and causes a higher mortality rate among older adults. balance impairment is independently associated with falls in patients with chronic obstructive pulmonary disease. well-known risk factors for falls in individuals with chronic obstructive pulmonary disease include advanced age, increased comorbidities, dyspnea, physical inactivity, muscle weakness, fear and decreased balance confidence, as well as lower extremity muscle weakness. it has been reported that there are functional deficiencies, lack of performance and postural control. according to the results of a recent study, it was found that chronic obstructive pulmonary disease is in the second place after osteoarthritis in chronic conditions where the prevalence of falls is highest. the prevalence of falls in individuals with chronic obstructive pulmonary disease is estimated to range from 25% to 46%.

Eligibility criteria:
inclusion criteria: * being diagnosed with copd according to criteria * not having had an attack in the last 2 months * volunteering to participate in the study * being 65 years or older * not having any mental or communication problems that prevent filling out the surveys to be used in the research. exclusion criteria: * having unstable copd * unstable angina, previous myocardial infarction, uncontrolled hypertension, cancer, neurological or musculoskeletal diseases with functional limitations * being currently addicted to alcohol or drugs * being in the process of copd exacerbation * having severe vision and hearing problems * having severe cognitive impairment * having had major surgery in the last few months
comparison of the osho protocol to a standard arm protocol of the german aml intergroup in patients with aml>60a

Conditions: Acute Myeloid Leukaemia

Summary: improvement of the treatment-results in elderly patients with acute myeloid leukemia through intensification of consolidation chemotherapy and/or allografting as consolidative immunotherapy

measuring efs depending on induction therapy

Eligibility criteria:
inclusion criteria: * patients of both sexes with age \> 60 years and newly diagnosed acute myeloid leukaemia as defined by new who classification * written informed consent exclusion criteria: * pretreatment of leukemia * no informed consent * simultaneous inclusion in other studies * mental disability * contraindication for intensive chemotherapy * aml fab m3 * contraindication for allogeneic stem cell transplantation * restriction of following organ functions: * creatinine-clearance \< 50 ml/min * cardiac ejection fraction \< 40 % * severe pulmonary restriction * bilirubin \> 2x uln; sgot and sgpt \> 4x uln * uncontrolled hypertension * severe uncontrolled metabolism disturbance * karnofsky-performance-score \< 70% * hepatitis c * other malignancy * age of unrelated donor \>70 years and age of related donor \>75 years

Keywords: aml
trial of two versus three doses of human papillomavirus (hpv) vaccine in india

Conditions: Cervical Cancer; Cervical Precancerous Lesions

Summary: the primary study hypothesis wasthat a two-dose human papillomavirus (hpv) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent hpv infection and cervical neoplasia caused by hpv types included in the vaccine. the government of india stopped vaccination in all the hpv vaccine trials in the country in april 2010 due to reasons not related to this study.

the suspension of vaccination resulted in girls receiving 3 doses (days 1, 60 and ≥180), receiving 2 doses (days 1 and ≥180), receiving 2 doses at days 1 and 60 due to incomplete treatment ("by default"), and receiving one dose by default. a first age and site-matched cohort of unvaccinated married women was recruited, starting in may 2012 to serve as the unvaccinated control group of women for the analysis of hpv incidence and persistence outcomes. a second age and site-matched (age and site matched to the vaccinated women undergoing screening) cohort of unvaccinated married women is being recruited starting in june 2017 and is to be used in addition to the first unvaccinated cohort for the assessment of the cervical neoplasia outcome.

Eligibility criteria:
inclusion criteria: * apparently healthy, ambulant girls aged 10 - 18 years * unmarried girls * girls with intact uterus * resident in the villages chosen for the study exclusion criteria: * girls with any severe and/or debilitating illness * past history of allergy to any medication
drowning incidents in danish harbours

Conditions: Drowning; Drown; Drowning; Anoxia; Drowning, Near; Drowning; Asphyxia; Drowning and Nonfatal Submersion; Drowning or Immersion of Unknown Intent; Drowning and Submersion, Undetermined Intent; Drowning and Submersion While in Natural Water; Drowning and Submersion Due to Sailboat Sinking; Drowning and Submersion Due to Fall Off Ship

Summary: a recent study reported significantly increased mortality from drowning-related out-of-hospital cardiac arrest in danish harbours compared to other public places (e.g., public pools, coastlines, and lakes). accurate and reliable data are necessary before establishing specific educational, preventative, rescue, or treatment strategies to reduce the number of drowning incidents in danish harbours and improve survival. therefore, it is essential to characterise drowning incidents in danish harbours and analyse risk factors associated with fatal drowning.

based on the gps coordinates and advanced text-searching, it is possible to identify drowning incidents in danish harbours and extract data from the danish prehospital drowning data. this study is a nationwide registry-based study with data from the danish prehospital drowning data from 2016 to 2023. in this study, we will use 30-day mortality to differentiate between fatal and non-fatal drowning. the primary objective is to estimate the yearly incidence of fatal and non-fatal drowning incidents in danish harbours treated by the ems from 2016 to 2023 and calculate the fatal to non-fatal ratio. the secondary objective is to assess risk factors associated with 30-day mortality.

Eligibility criteria:
inclusion criteria: * all the patients registered in the danish prehospital drowning data from 2016-2023 will be assessed for inclusion and * incidents registered at gps coordinates corresponding to a danish harbour or * incidents identified using advanced text-search algorithm searching for "harbour"-related words exclusion criteria: * patients without a 30-day follow-up (e.g., due to missing or invalid civil registration numbers) and patients with a valid dnar code will be excluded from the mortality analysis.

Keywords: danish drowning formula danish prehospital drowning data denmark registry database cohort drowning harbour emergency medical service submersion